LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

Subjects

Subjects :

Immunologic diseases. Allergy
RC581-607

Details

Language :

English

ISSN :

20538790

Volume :

10

Issue :

Suppl 1

Database :

Directory of Open Access Journals

Journal :

Lupus Science and Medicine

Publication Type :

Academic Journal

Accession number :

edsdoj.0b94597c52ec4a419d6df6f484ccda0a

Document Type :

article

Full Text :

https://doi.org/10.1136/lupus-2023-KCR.21